Cambridge Oncometrix test is based on unique biomarkers and algorithms to create medicals devices aimed at the non-invasive prostate health monitoring and identification on men who can safely avoid prostate biopsy and mpMRI. Main competitive advantages of the technology are its high negative predictive value (NPV), low cost of the test, stability of the markers, and simplicity and speed of analysis.
A proof-of-concept clinical trial verified that the test can be used a triage test and will significantly reduce the number of (i) expensive pre-biopsy MRI scans, (ii) unnecessary prostate biopsies and its complications, (iii) secondary care referrals. Due to the nature of the markers Cambridge Oncometrix diagnostic technology can be implemented in laboratory, point-of-care, or home test devices. Further, it also will permit longitudinal monitoring and self-monitoring of patients at low costs to identify men who will benefit from the costly and burdensome prostate cancer diagnostic pathway.
Norwich Research Park
Telephone: 01603 274 521